Cargando…
Impact of genetic alterations on mTOR-targeted cancer therapy
Rapamycin and its derivatives (rapalogs), a group of allosteric inhibitors of mammalian target of rapamycin (mTOR), have been actively tested in a variety of cancer clinical trials, and some have been approved by the Food and Drug Administration for the treatment of certain types of cancers. However...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Sun Yat-sen University Cancer Center
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845552/ https://www.ncbi.nlm.nih.gov/pubmed/23489586 http://dx.doi.org/10.5732/cjc.013.10005 |